- Company
- Tylenol-focused sales for COVID-19-related use dispersed
- by Kim, Jin-Gu Sep 14, 2022 05:50am
- The stock shortage of major over-the-counter drugs used to relieve symptoms of COVID-19, such as general cold medicines and antipyretic analgesics, has been prolonged due to the resurgence of COVID-19. In this prolonged shortage, the demand that had been concentrated on Tylenol is being dispersed to other drugs. Tylenol was the only major hou
- Company
- Novartis' application for voluntary retirement is closed
- by Sep 14, 2022 05:50am
- The application for ERP, which is underway by Novartis Korea, has ended. Attention is focusing on whether the relatively quiet voluntary retirement will be completed without any problems. According to the pharmaceutical industry on the 8th, the application for voluntary retirement, which was conducted by Novartis Korea for about two weeks,
- Company
- Hanmi’s Rolontis receives US FDA marketing approval
- by Kim, Jin-Gu Sep 13, 2022 05:52am
- Hanmi Pharmaceutical’s neutropenia treatment ‘Rolontis (US product name: Rolvedon)' received approval from the US FDA. Hanmi Pharmaceutical and its partner Spectrum Pharmaceuticals announced on the 9th (local time) that it had received written notice of approval allowing for the marketing authorization of Rolontis from the FDA. This is t
- Company
- Unilateral voluntary retirement
- by Sep 8, 2022 05:59am
- The GSK labor union of Korea has taken legal action, insisting on the management's unilateral voluntary retirement. The company is not taking any action, but the inside is "like the calm before the storm" as legal battles are predicted. Novartis Korea, where voluntary retirement is being carried out relatively quietly, is also nervous until t
- Company
- Sales of immuno-cancer drugs exceeded 200 billion won
- by Sep 8, 2022 05:58am
- In the first half of this year, the domestic immune anticancer drug market surpassed 200 billion won. In particular, Opdivo's performance, which showed his endurance, was remarkable. Opdivo sales increased 41% from the previous year, surpassing 50 billion won in half-year sales. According to IQVIA, a pharmaceutical market research firm, th
- Company
- Zolgensma, which is the same price as an apartment
- by Moon, sung-ho Sep 8, 2022 05:58am
- With ultra-high-priced treatments from global pharmaceutical companies newly entering the benefit range this year, human "risk management" is emerging as an issue at clinical sites. Since the treatment is so expensive, "risk" management issues such as damage and loss that may occur during administration are acting as a key issue. Kymriah,
- Company
- Godex’s price to be cut further under PVA
- by Nho, Byung Chul Sep 7, 2022 05:52am
- Celltrion Pharm’s liver disease treatment Godex cap. is experiencing ‘double trouble,’ being subject to Price-Volume Agreement negotiations after reimbursement reevaluations. According to industry sources, Godex’s price will be cut by &8361;15 per capsule (4% reduction) from &8361;371 to &8361;356 as of the 1st of this month.
- Company
- Poziotinib responds 100% to pts with lung cancer mutations
- by Sep 7, 2022 05:52am
- Poziotinib, a new lung cancer drug exported by Hanmi Pharmaceutical, was found to have a significant effect on the G778 mutation, which is common in patients with HER2 Exxon20 insertion mutation. As a result of ZENITH20 clinical subanalysis, 12 patients showed 100% response, and PFS was also longer than other HER2 Exxon20 mutants. In particul
- Company
- Kisqali’s sales surge, Ibrance’s sales falter
- by Sep 6, 2022 05:51am
- Competition for breast cancer-treating cyclin-dependent kinases (CDK) 4/6 inhibitors in the market are heating up. Kisqali, which was the last to enter the market, has grown rapidly in the first half of this year and exceeded sales of the runner-up product in the market, Verzenio. Ibrance, the sole leader in the market, has also seen a dow
- Company
- Prevenar 13 set to make ₩40B this year
- by Nho, Byung Chul Sep 5, 2022 05:55am
- Pfizer’s Prevenar 13 was found to be maintaining its overwhelming 70% share in the pneumococcal vaccine market. According to its distribution & shipment performance data, sales of Prevenar 13 in 1H this year reached &8361;19.4 billion, and its annual sales are expected to exceed that of the &8361;38.1 made last year. In terms of
